Loading...
Market
Primary focus of NIH policy changes post COVID-19 report by mid-2025?
2
Resolution / Starting Odds
Increased transparency • 25%
Funding restrictions • 25%
Enhanced oversight • 25%
No major changes • 25%
NIH official policy documents and announcements
Story
House Report: NIH Funded Wuhan Research, Linked to 20M Deaths, $25T Cost
Dec 2, 2024, 05:32 PM
The Select Subcommittee on the Coronavirus Pandemic has released its final report, detailing a comprehensive investigation into the origins of the COVID-19 virus. The report highlights several key findings, including evidence that some officials attempted to obscure the facts regarding the virus's origins. It also confirms that the National Institutes of Health (NIH) funded gain-of-function research in Wuhan, China, until 2022, which potentially contributed to the emergence of the virus, resulting in over 20 million deaths and an estimated cost of $25 trillion. The investigation faced obstacles from the Biden Administration, which is accused of obstructing the committee's efforts. Additionally, the report criticizes Dr. Anthony Fauci and his Senior Advisor for their involvement in research practices and their attempts to suppress scientific discourse on the virus's origins.
View original story
Similar markets
Increased funding for infectious disease research • 25%
Increased funding for chronic disease research • 25%
Increased funding for mental health research • 25%
Other funding priorities • 25%
COVID-19 management • 25%
Cancer research • 25%
Mental health • 25%
Other • 25%
Increased oversight on research funding • 25%
Reevaluation of pandemic response strategies • 25%
Improved fraud prevention measures • 25%
Public communication and trust-building • 25%
Academic freedom • 25%
Research funding allocation • 25%
Public health initiatives • 25%
Other focus area • 25%
COVID-19 Response • 25%
Chronic Disease • 25%
Mental Health • 25%
Other • 25%
Pandemic Preparedness • 25%
Chronic Disease Research • 25%
Mental Health Initiatives • 25%
Other • 25%
COVID-19 research • 25%
Chronic diseases • 25%
Mental health • 25%
Other emerging health issues • 25%
Vaccine development • 25%
Research oversight • 25%
International cooperation • 25%
Public health infrastructure • 25%
Yes • 50%
No • 50%
Increase in funding • 25%
Decrease in funding • 25%
No change • 25%
Policy overhaul • 25%
Focus on pandemic preparedness • 25%
Reform in pharmaceutical company collaborations • 25%
Emphasis on non-pharmaceutical research • 25%
Other policy initiative • 25%